Mixed Treatment Comparison of the Treatment Discontinuations of Biologic Disease-Modifying Antirheumatic Drugs in Adults with Rheumatoid Arthritis
Open Access
- 1 November 2012
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 46 (11), 1491-1505
- https://doi.org/10.1345/aph.1r203
Abstract
BACKGROUND: Introduction of biologic disease-modifying antirheumatic drugs (DMARDs) has considerably changed treatment options for rheumatoid arthritis (RA) over the past decade. Very little information is available on comparative discontinuation rates of the biologics. OBJECTIVE: To compare treatment discontinuations for 9 biologic DMARDs in adults with RA. METHODS: We searched electronic databases through May 2012 to retrieve randomized controlled trials (RCTs) of patients with RA that compared biologic DMARDs with placebo or another biologic DMARD. The primary outcome was treatment discontinuation during the blinded phase of the trials, measured as overall withdrawals, withdrawals resulting from lack of efficacy, and withdrawals resulting from adverse events. Random-effects meta-analysis estimated the effect size for individual agents, and adjusted indirect comparisons were made between biologics using mixed treatment comparisons (MTC) meta-analysis. RESULTS: Forty-four trials were included in the analysis. In comparison with placebo, biologics were less likely to be withdrawn because of lack of efficacy (OR 0.22, 95% CI 0.17 to 0.27) and more likely to be withdrawn because of an adverse event (OR 1.41, 95% CI 1.16 to 1.70). Based on the MTC, certolizumab had the most favorable overall withdrawal profile, followed by etanercept and rituximab. Certolizumab had lower relative withdrawal rates resulting from lack of efficacy than adalimumab, anakinra, and infliximab. Anakinra had higher relative withdrawal rates resulting from lack of efficacy than most other biologics. Certolizumab and infliximab had more, while etanercept had fewer, withdrawals because of adverse events than most other drugs. CONCLUSIONS: Based on MTC using data from RCTs, differences in discontinuation rates were observed, generally favoring certolizumab, etanercept, and rituximab over other biologic DMARDs. These potential differences need to be further explored in head-to-head trials or well-conducted observational studies.Keywords
This publication has 54 references indexed in Scilit:
- Meta‐analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid ArthritisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
- A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overviewCMAJ : Canadian Medical Association Journal, 2009
- Bayesian Meta-Analysis of Multiple Treatment Comparisons: An Introduction to Mixed Treatment ComparisonsValue in Health, 2008
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals Of The Rheumatic Diseases, 2008
- Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safetyBMC Musculoskeletal Disorders, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- The efficacy of inhibiting tumour necrosis factor and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisonsRheumatology, 2007
- Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Direct medical costs and their predictors in patients with rheumatoid arthritisArthritis & Rheumatism, 2003
- Current methods of the U.S. Preventive Services Task Force: A review of the processAmerican Journal of Preventive Medicine, 2001